La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Olaplex Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Olaplex Hldgs..

Olaplex Hldgs (NASDAQ:OLPX) Azioni, Catena delle Opzioni

OLAPLEX HOLDINGS INC

Olaplex Hldgs

Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.

UBS analyst Michael Goldsmith maintains UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) with a Buy and lowers the price target from $50 to $45.

News

Price Target

Analyst Ratings

UBS Maintains Buy on UDR, Lowers Price Target to $45

Stifel analyst Parker Lane maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Buy and lowers the price target from $45 to $40.

KVYO

Stifel Maintains Buy on Klaviyo, Lowers Price Target to $40

UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) with a Buy and lowers the price target from $37 to $35.

SNDX

UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $35

Stifel analyst Brian Brophy assumes Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) with a Buy rating and raises Price Target to $7.

Initiation

CTOS

Stifel Assumes Custom Truck One Source at Buy, Raises Price Target to $7

Canadian Pacific Kansas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CP#NYSE">CP</a>) has outperformed the market over the past 20 years by 4.37% on an annualized basis producing an average annual return of 12.82%. Currently, Canadian Pacific Kansas has a market capitalization of $75.78 billion. 
Buying $100 In CP: If an investor had bought $100 of CP stock 20 years ago, it would be worth $1,118.83 today based on a price of $81.16 for CP at the time of writing.
<h3>Canadian Pacific Kansas's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752590720_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

UBS analyst Michael Goldsmith maintains Mid-America Apartment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) with a Sell and lowers the price target from $149 to $142.

UBS Maintains Sell on Mid-America Apartment, Lowers Price Target to $142

Stifel analyst Tore Svanberg upgrades Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) from Sell to Hold and raises the price target from $18 to $25.

Upgrades

AOSL

Stifel Upgrades Alpha & Omega to Hold, Raises Price Target to $25

On July 7, 2025, SRx Health Solutions, Inc. (the "Company") and an investor (the "Lead Investor"), entered into a common share purchase agreement (the "ELOC Purchase Agreement"), which provides that subject to the terms and conditions set forth therein, the Company may sell to the Investor up to the lesser of (i) $50,000,000 of the Company's common shares, no par value (the "Common Share") and (ii) the Exchange Cap (as defined below) (subject to certain exceptions provided in the ELOC Purchase Agreement) (the "Total Commitment"), from time to time during the term of the ELOC Purchase Agreement.
&nbsp;
Additionally, on July 7, 2025, the Company and the Lead Investor entered into a registration rights agreement (the "ELOC RRA"), pursuant to which the Company agreed to file a registration statement with the United States Securities and Exchange Commission ("SEC") covering the resale of Common Shares that are issued to the Lead Investor under the ELOC Purchase Agreement (the "Registration Statement").
&nbsp;
Under the terms and subject to the satisfaction of the conditions set forth in the ELOC Purchase Agreement, the Company has the right, but not the obligation, to sell to the Lead Investor, and the Lead Investor is obligated to purchase, up to the Total Commitment. Such sales of Common Shares by the Company, if any, will be subject to certain limitations as set forth in the ELOC Purchase Agreement, and may occur from time to time, at the Company's sole discretion, over the period commencing on the date that all of the conditions to the Company's right to commence such sales are satisfied, including that the registration statement referred to above is declared effective by the SEC and a final form of the prospectus included therein is filed with the SEC (the "Commencement Date") and ending upon the expiration of the Registration Statement pursuant to Rule 4125(a)(5) of the Securities Act of 1933, as amended, or otherwise upon the termination of the ELOC Purchase Agreement as provided therein. The Lead Investor has no right to require the Company to sell any Common Shares to the Lead Investor, but the Lead Investor is obligated to make purchases as the Company directs, subject to satisfaction of the conditions set forth in the ELOC Purchase Agreement.
&nbsp;
Upon entering into the ELOC Purchase Agreement, the Company agreed to issue to the Lead Investor $1,000,000 worth of the Company's Common Stock, valued at the VWAP Purchase Price (as such term is defined in the ELOC Purchase Agreement), which price is at a discount to the then-current closing sale price, as of such date (the "Commitment Shares") as consideration for the Lead Investor's commitment to purchase Common Shares upon the Company's direction under the ELOC Purchase Agreement. The Company also agreed to pay the Lead Investor up to $35,000 for its reasonable expenses under the ELOC Purchase Agreement.
&nbsp;
From time to time from and after the Commencement Date, on any business day selected by the Company where the closing sale price on the applicable eligible market, or quotation service is equal to or greater than $0.25, subject to the satisfaction of all of the conditions set forth in the ELOC Purchase Agreement, the Company shall have the right, but not the obligation, to direct the Lead Investor, to purchase the applicable VWAP Purchase Share Amount (as such term is defined in the ELOC Purchase Agreement), not to exceed the agreed upon maximum, at the applicable VWAP Purchase Price therefor, which price is at a discount to the then-current closing sale price, provided that the Lead Investor's aggregate committed obligation pursuant to the foregoing shall not exceed $50,000,000.00.

Financing

Offerings

SRXH

SRx Health Solutions Enters $50M Equity Line Of Credit Agreement On July 7, Issuing $1M In Commitment Shares And Capping Ownership At 19.99% Without Shareholder Approval

<a href="https://www.wsj.com/business/autos/tesla-troy-jones-north-american-sales-leaves-b2ac616d">https://www.wsj.com/business/autos/tesla-troy-jones-north-american-sales-leaves-b2ac616d</a>

General

TSLA

'Tesla's Top North American Sales Executive Leaves Amid Slump'- WSJ

UBS analyst Joshua Chan maintains Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) with a Buy and lowers the price target from $500 to $480.

UBS Maintains Buy on Gartner, Lowers Price Target to $480

UBS analyst Ami Probandt maintains Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) with a Buy and lowers the price target from $24 to $21.

UBS Maintains Buy on Independence Realty Trust, Lowers Price Target to $21

Piper Sandler analyst Edward Tenthoff maintains NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) with a Overweight and lowers the price target from $36 to $15.

NXTC

Piper Sandler Maintains Overweight on NextCure, Lowers Price Target to $15

Piper Sandler analyst Ryan Todd maintains BP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>) with a Neutral and raises the price target from $32 to $35.

Piper Sandler Maintains Neutral on BP, Raises Price Target to $35

CYCC

Cyclacel Pharmaceuticals Shares Resume Then Halt Again On Circuit Breaker, Now Up 398.5%

UBS analyst Arpine Kocharyan maintains Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Buy and lowers the price target from $49 to $40.

UBS Maintains Buy on Six Flags Entertainment, Lowers Price Target to $40

Piper Sandler analyst Ryan Todd maintains ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) with a Overweight and raises the price target from $113 to $123.

Piper Sandler Maintains Overweight on ConocoPhillips, Raises Price Target to $123

UBS analyst Michael Goldsmith maintains Essex Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) with a Neutral and lowers the price target from $297 to $295.

UBS Maintains Neutral on Essex Property Trust, Lowers Price Target to $295

Piper Sandler analyst Ryan Todd maintains Shell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) with a Overweight and raises the price target from $83 to $84.

SHEL

Piper Sandler Maintains Overweight on Shell, Raises Price Target to $84

When Xero announced its $2.5 billion acquisition of Melio, <a href="https://www.benzinga.com/fintech">the fintech world</a> took notice. Melio isn't the biggest player in U.S. SMB payments—its 80,000 customers and $30 billion in annual bill-pay volume are dwarfed by Bill.com's $338 billion run-rate—but its strengths run deep, and that's exactly why Xero pounced. What makes Melio a unique asset for Xero? Let's take a closer look.
The Numbers Behind the Deal
Despite only capturing about 0.05% of the $58 trillion U.S. B2B payments market, Melio commands nearly 9% of Bill.com's payment volume with just a sixth of the customer base. That means Melio's users are spending more and sticking around. For Xero, the acquisition is transformative: North America subscribers jump from 422,000 to nearly 500,000, and average revenue per user (ARPU) skyrockets from $14 to $49—tripling Xero's U.S. revenue overnight.
Fraud, Risk, and the Technical Edge
In a market where failed fraud models can be fatal to a business, Melio's technical edge is its calling card. "This is a deeply technical fintech product that has the fraud and risk completely dialed… millions and millions of transactions have run through, they fine-tuned it, and it's hard&#8230; I don't think enough people talk about that," says Michael Gilroy, partner at Marathon Partners and former Melio board member. Melio's ability to monetize payments at a gross margin of 20% or more—while keeping loss ratios in check—is a feat that many rivals cannot replicate.
Embedded Networks: Melio's Secret Weapon
Beyond the tech, Melio's go-to-market strategy sets it apart. Rather than just selling directly, Melio powers bill-pay for giants like Shopify, FIS, and dozens of regional banks. "What Melio did brilliantly, because this is all about network effects, is they said, ‘Hey, not only are we gonna go direct, but we're also gonna build an embedded solution.' And that embedded solution is where the market is going, frankly," Gilroy explains. This B2B-to-SMB syndication engine is something Xero lacked—and now instantly inherits.
Viral Growth and Platform Stickiness
Melio's network effects aren't just theoretical. "I did this quick sprint with Matan and the data science team, and we calculated K-factor, and it was, like, off the charts… SMBs are paying their bills, and people that are receiving them from Melio are not customers yet, and then they sign up to be," Gilroy recalls. This viral loop keeps acquisition costs low and makes Melio's platform unusually sticky—a rare feat in the B2B fintech sector.
The Power of a Well-Balanced Platform
Melio's success comes from more than just tech or partnerships—it's the combination. "It would be hard to pick [between partnerships, network, or simplicity] because if you lose one of them, the other two fall down," Gilroy says. "It kind of all breaks down." That synergy is what Xero is truly buying: a platform that's technically robust, simple, and deeply embedded across the ecosystem.
Why It Matters
Xero isn't just acquiring a payments tool—it's buying Melio's technical depth, viral network, and platform partnerships. If Xero can integrate these strengths, it stands to become a true challenger to Intuit in the U.S. cloud accounting and payments market.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46413961/june-inflation-cpi-report">June Inflation Lands As Expected — But Cooler Core Reading Fuels Fed Rate Cut Hopes</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

Exclusives

Why Xero Took A $2.5 Billion Bet On This B2B Payments Startup

Piper Sandler analyst Ryan Todd maintains HF Sinclair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>) with a Overweight and raises the price target from $43 to $53.

DINO

Piper Sandler Maintains Overweight on HF Sinclair, Raises Price Target to $53

Press Releases

Olaplex Holdings, Inc. to Report Third Quarter Fiscal 2024 Financial Results on November 7th

Earnings

OLAPLEX Reports Third Quarter 2024 Results

Legal

Grabar Law Office Is Investigating Claims On Behalf of Long-Term Shareholders of Olaplex Holdings, Inc. (NASDAQ: OLPX); Telephone and Data Systems, Inc. (NYSE: TDS); Methode Electronics, Inc. (NYSE: MEI); and Equinix, Inc. (NASDAQ: EQIX)

Grabar Law Office is Investigating Claims On Behalf of Long-Term Shareholders of Extreme Networks, Inc. (NASDAQ: EXTR); Newmont Corporation (NYSE: NEM); Domino's Pizza Corp. (NASDAQ: DPZ); and Olaplex Holdings, Inc. (NASDAQ: OLPX)

GRABAR LAW OFFICE IS INVESTIGATING CLAIMS ON BEHALF OF LONG-TERM SHAREHOLDERS OF ORIGIN MATERIALS, INC. (NASDAQ: ORGN); OLAPLEX HOLDINGS, INC. (NASDAQ: OLPX); TELEPHONE AND DATA SYSTEMS, INC. (NYSE: TDS); AND METHODE ELECTRONICS, INC. (NYSE: MEI)

Olaplex Holdings, Inc. to Report Fourth Quarter and Fiscal 2024 Financial Results on March 4th

Olaplex Holdings, Inc. Announces Participation in the Raymond James 46th Annual Institutional Investors Conference on March 5th

OLAPLEX Reports Fourth Quarter and Fiscal Year 2024 Results

Olaplex Holdings, Inc. to Report First Quarter Fiscal 2025 Financial Results on May 8th

OLAPLEX Reports First Quarter 2025 Results

EQIX

EXTR

OLPX

ORGN

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Upexi

Usana Health Sciences

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Comments

Olaplex Hldgs

Olaplex Hldgs (OLPX) Opzioni

Olaplex Hldgs (NASDAQ:OLPX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO